379 studies found for:    "HIV Seronegativity" [CONDITION]
Show Display Options
Rank Status Study
21 Completed Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
22 Completed Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Lipopeptides LIPO-4
23 Completed ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1;   Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo;   Biological: MN rgp120/HIV-1  placebo
24 Terminated Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Drug: Tenofovir DF
25 Recruiting Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
Conditions: HIV Infection;   HIV Seronegativity
Intervention:
26 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
27 Completed Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
Conditions: HIV Infections;   Vitamin A Deficiency;   HIV Seronegativity
Intervention: Drug: Vitamin A
28 Completed Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV (vCP205)
29 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
30 Withdrawn Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: MN rsgp120/HIV-1
31 Completed Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1
32 Completed Botanical/Drug Interactions in HIV: Glucuronidation
Condition: HIV Seronegativity
Intervention: Drug: silymarin
33 Completed A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Procedure: Flexible Sigmoidoscopy;   Procedure: Rectal Biopsy
34 Completed Peer Mentors for Adolescents in HIV Affected Families
Conditions: Adolescent Behavior;   Health Behavior;   HIV Seronegativity
Intervention: Behavioral: Peer mentoring program
35 Completed Long-Term Effects of HIV Exposure and Infection in Children
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
36 Completed Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
Conditions: HIV Infections;   Pregnancy;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
37 Completed Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
38 Recruiting CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
Conditions: Patient Adherence;   HIV Seronegativity
Intervention: Device: SoC + iTab
39 Completed A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: MTP-PE/MF59;   Biological: Env 2-3
40 Recruiting Pre-exposure Prophylaxis Accessibility Research and Evaluation 2
Conditions: PrEP Uptake;   HIV Seronegativity
Intervention: Behavioral: Informed Risk Score

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years